Companies: 10,795·Total market cap: $144.5T

Hadasit Bio-Holdings Ltd

Hadasit Bio-Holdings Ltd

HSITFOTCHealthcare

$0.12

+$0.00(+0.00%)

Market Cap$1330623

P/E Ratio—

52W High$0.13

52W Low$0.12

Avg Volume76.8

Open$0.12

Beta0.49

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Hadasit Bio-Holdings Ltd（HSITF）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · HSITF · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-0.18Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)0.00Full revenue history

Dividend Yield44.55%Dividend history

Shares Outstanding11.1MShares outstanding history

Next EarningsTBAEarnings history

探索 Hadasit Bio-Holdings Ltd 数据

分析师预测—

盈利EPS $-0.31+88.21%

财务快照

FY 2024Revenue$0.00

202220232024

FY 2024Net Income-$3.5M▲ +88.14% YoY

202220232024

FY 2024EPS$-0.31▲ +88.21% YoY

202220232024

TTM:Revenue: $0.00Net Income: -$2.1MEPS: $-0.18View income statement →

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Hadasit Bio-Holdings Ltd

$0.12+0.00%$1.3M #2

AccuStem Sciences Limited

$0.13-7.14%$0 #3

Cell Source, Inc.

$0.82+2.50%$36.9M #4

CareView Communications, Inc.

$0.05+19.09%$32.1M #5

Gemina Laboratories Ltd.

$0.05+0.00%$3.8M #6

Institute of Biomedical Research Corp.

$0.00+15.38%$4.1M

股票表现

1D+0.00%

1W+0.00%

1M+0.00%

3M+0.00%

YTD+0.00%

1Y+0.00%

5Y-95.60%

关于 Hadasit Bio-Holdings Ltd

CEOYuval Adar

IPO DateOct 27, 2010

Employees2

CountryIL

Websitehbl.co.il

Hadasit Bio-Holdings Ltd an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and …

Biotechnology HealthcareOTCIL

关于股票概览与关键数据

Hadasit Bio-Holdings Ltd（HSITF）是 Biotechnology 行业的 Healthcare 类公司，于 Oct 27, 2010 在 OTC 上市。截至最近交易日，HSITF 股价为 $0.12，市值约为 $1.3M。过去12个月累计回报 +0.00%，年初至今回报 +0.00%。

2024 财年 Hadasit Bio-Holdings Ltd 营收 —。完整财务数据（营收历史、盈利、资产负债表）请使用上方标签页。

常见问题

截至最近一个交易日，Hadasit Bio-Holdings Ltd（HSITF）股价为 $0.12，在 OTC 上市，52周区间为 $0.12 – $0.13。

HSITF 最新股价HSITF quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议